Murray Stewart
Director/Board Member at X4 PHARMACEUTICALS, INC.
Net worth: 169 317 $ as of 2024-04-29
Murray Stewart active positions
| Companies | Position | Start | End |
|---|---|---|---|
| X4 PHARMACEUTICALS, INC. | Director/Board Member | 2019-03-28 | - |
| Chief Tech/Sci/R&D Officer | 2022-11-28 | 2023-07-31 | |
| Vivli Center For Global Clinical Research Data | Director/Board Member | - | - |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Director/Board Member | - | - |
Career history of Murray Stewart
Former positions of Murray Stewart
| Companies | Position | Start | End |
|---|---|---|---|
| VECTIVBIO HOLDING AG | Director/Board Member | 2021-09-01 | 2023-06-25 |
| Independent Dir/Board Member | 2021-09-01 | 2023-06-25 | |
| AMARIN CORPORATION PLC | Director/Board Member | 2023-01-09 | 2023-03-05 |
| Independent Dir/Board Member | 2023-01-09 | 2023-03-05 | |
| RHYTHM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2018-10-14 | 2021-09-09 |
| NOVELION THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 2017-11-26 | 2018-10-16 |
| GSK PLC | Chief Tech/Sci/R&D Officer | 2014-03-31 | 2017-10-31 |
| Corporate Officer/Principal | - | - |
Training of Murray Stewart
| The University of Southampton | Doctorate Degree |
Statistics
International
| United States | 4 |
| United Kingdom | 3 |
| Switzerland | 3 |
Operational
| Director/Board Member | 5 |
| Chief Tech/Sci/R&D Officer | 4 |
| Independent Dir/Board Member | 2 |
Sectoral
| Health Technology | 8 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| AMARIN CORPORATION PLC | Health Technology |
| RHYTHM PHARMACEUTICALS, INC. | Health Technology |
| GSK PLC | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada. | Health Technology |
| Vivli Center For Global Clinical Research Data | |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Murray Stewart
- Experience
